Clinical stage pharmaceutical development Company
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) announced on Friday that it has enrolled 75% of its enrollment target, (113 patients) for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19.
The Company has projected that the study will be completed in November 2020 with a planned data readout before the end of Q4, 2020.
To find out the latest on this trial,
click here.
The clinical stage pharmaceutical development Company has been busy with this study, titled:
“A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease,” which enrolled its
100th patient earlier this week.
The intent is to gather a total of 150 patients who will either be treated using an existing standard of care, or standard of care plus Ifenprodil 60 mg, and doctors will see if there is an improvement in a number of secondary endpoints (mortality, blood oxygen levels, time in intensive care, time to mechanical ventilation).
The Company stressed that it is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.